Alison Kanski

The Bladder Cancer Advocacy Network organized the UC-GENOME study and is now offering more grant funding to support clinical trials in bladder cancer.

The company is exploring VAL-083 across the spectrum of newly diagnosed and recurrent unmethylated and methylated MGMT glioblastoma.

Researchers implemented a cloud-based software to integrate genomic and other patient data and support virtual MTB case reviews across Providence's more than 50 hospitals.

Gaps in the biomarker testing process and knowledge deficiencies are keeping nearly two-thirds of lung cancer patients from receiving precision oncology treatments, research shows.

Groups representing diagnostics and pharma firms advocate for removing barriers to comprehensive genomic profiling to improve patients' access to precision oncology.

The firm's newer precision oncology drugs, including Lorbrena, Braftovi, and Mektovi, however, continued their sales growth in Q3.

An Australian study explored the predictive and prognostic ability of two PET imaging-based biomarkers to guide treatment with Novartis' radioligand therapy.

The trial is supported by a consortium of seven large pediatric centers that aim to improve tumor surveillance and understanding of cancer predisposition syndromes.

Results from the DreamSeq trial showed that more melanoma patients who received frontline immunotherapy were alive at two years compared to frontline targeted therapy.

The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.